Skip to main content

Table 1 Clinical characteristics of neonates between C.albicans and non-C.albicans

From: Epidemiology of Candida albicans and non-C.albicans of neonatal candidemia at a tertiary care hospital in western China

Variable

C.albicans mean (95%CI) or n (%)

non-C.albicans mean (95%CI) or n (%)

P value

odds ratio (OR) (95%CI)

Demographics

 gestational age (wks)

31.7 (27.6, 35.8)

31.5 (27.7, 36.3)

0.765

 

 birth weight (g)

1670.0 (962.1,2377.9)

1417.6 (777.1,2058.1)

0.128

 

 male gender, n (%)

22 (73.3)

22 (56.4)

0.150

0.47 (0.17–1.32)

 admission age

2.1 (2.0, 6.2)

1.1 (0.6, 1.6)

0.138

 

Risk factors

 necrotizing enterocolitis

5 (16.7)

12 (30.8)

0.183

2.22 (0.69–7.21)

 neurodevelopmental impairment

7 (23.3)

8 (20.5)

0.778

0.85 (0.27–2.68)

 maternal underlying diseases

12 (40.0)

18 (46.2)

0.609

1.29 (0.50–3.36)

 assisted reproductive technology

5 (16.7)

19 (48.7)

0.008

4.75 (1.51–14.96)

 vaginal birth

19 (63.3)

23 (59.0)

0.713

1.20 (0.45–3.20)

 fetal membrane rupture (h)

16.4 (28.4, 61.2)

26.6 (36.0, 89.2)

0.459

 

 congentital diseases

13 (43.3)

24 (61.5)

0.135

2.09 (0.80–5.51)

 abdominal surgery

4 (13.3)

6 (15.4)

0.811

1.18 (0.30–4.63)

 mechanical ventilation

14 (46.7)

29 (74.4)

0.021

3.31 (1.20–9.15)

 central venous catheter

14 (46.7)

27 (69.2)

0.061

2.57 (0.96–6.91)

 intubation

10 (33.3)

21 (53.8)

0.092

2.33 (0.87–6.26)

 pulmonary active substance use

7 (23.3)

9 (23.1)

0.980

0.99 (0.32–3.04)

 steroids use

6 (20.0)

9 (23.1)

0.759

1.20 (0.38–3.84)

 antacid use

3 (10.3)

8 (21.1)

0.250

2.31 (0.56–9.63)

 total parenteral nutrition

23 (76.7)

36 (92.3)

0.080

3.65 (0.86–15.57)

 hospitalization duration (d)

43.8 (19.1, 78.5)

49.1 (26.6, 71.6)

0.367

 

 3rdcephalosporins use

16 (55.2)

23 (59.0)

0.754

1.17 (0.44–3.08)

 carbapenems use

21 (70.0)

30 (76.9)

0.517

1.43 (0.49–4.20)

 vancomycin use

4 (13.3)

6 (15.4)

0.811

1.18 (0.30–4.63)

 multiple antibiotic use

19 (63.3)

18 (46.2)

0.158

0.50 (0.19–1.31)

 antibiotic therapeutic duration (d)

28.1 (10.0, 46.2)

38.0 (19.3, 56.7)

0.033

 

 prophylaxis antifungal therapy

19 (63.3)

32 (82.1)

0.084

2.65 (0.88–7.99)

 antifungal therapeutic duration (d)

7.9 (2.3, 13.5)

8.8 (2.3, 15.3)

0.535

 

Outcome

 death

1 (3.3)

5 (12.8)

0.197

4.27 (0.47–38.62)